This NG2-dependent survival signaling via the PI3/AKT axis results in increased glioma cell resistance to treatment with chemotherapeutic drugs, including carboplatin, cisplatin, doxorubicin, and TNFα. This evidence concerns the gene CSPG4 and central nervous system cancer.